Aspirin may reduce cancer mortality
This article was originally published in The Tan Sheet
Executive Summary
Regular aspirin use may lower the risk of cancer-specific mortality among patients diagnosed with nonmetastatic colorectal cancer, according to a Journal of the American Medical Association study. Of the 840 women and 439 men participating in the Nurses' Health Study and the Health Professionals Follow-Up Study, 222 died from colorectal cancer. Only 15 percent of these deaths occurred among regular aspirin users, whereas 19 percent of deaths occurred among subjects who did not regularly use aspirin after their diagnosis, according to lead researcher Andrew Chan of Massachusetts General Hospital and Harvard Medical School and his associates. The results suggest this cancer type is sensitive to aspirin's potential anticancer effect, though cyclo-oxygenase-2-negative tumors might be aspirin-resistant
You may also be interested in...
Study Suggests Aspirin Use Enhances Survival After Breast Cancer
Aspirin use after the diagnosis of stage I to III breast cancer was associated with a decreased risk of breast cancer death and distant recurrence - when cancer has metastasized to another part of the body - according to results from the ongoing Nurses' Health Study
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.